Juno Therapeutics, Inc. (NASDAQ:JUNO) Stake Lessened by Wasatch Advisors Inc.

Wasatch Advisors Inc. decreased its holdings in Juno Therapeutics, Inc. (NASDAQ:JUNO) by 1.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 651,016 shares of the biopharmaceutical company’s stock after selling 10,982 shares during the period. Wasatch Advisors Inc. owned approximately 0.57% of Juno Therapeutics worth $29,205,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of JUNO. The Manufacturers Life Insurance Company grew its position in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares in the last quarter. Pacad Investment Ltd. acquired a new stake in shares of Juno Therapeutics during the second quarter worth approximately $105,000. Advisor Group Inc. boosted its holdings in Juno Therapeutics by 141.1% in the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,439 shares during the period. QS Investors LLC acquired a new position in Juno Therapeutics in the second quarter worth $135,000. Finally, Wellington Shields & Co. LLC acquired a new position in Juno Therapeutics in the third quarter worth $202,000. Hedge funds and other institutional investors own 70.37% of the company’s stock.

Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) traded up $2.17 during trading hours on Thursday, reaching $56.73. The company’s stock had a trading volume of 1,263,213 shares, compared to its average volume of 2,029,855. Juno Therapeutics, Inc. has a 52-week low of $17.52 and a 52-week high of $63.45. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The firm had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. During the same period in the prior year, the business posted ($0.57) earnings per share. The business’s revenue was up 115.4% compared to the same quarter last year. research analysts predict that Juno Therapeutics, Inc. will post -4.02 EPS for the current fiscal year.

A number of equities analysts have commented on JUNO shares. BTIG Research raised shares of Juno Therapeutics from a “sell” rating to a “neutral” rating in a report on Monday, August 28th. Zacks Investment Research cut Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 28th. Wells Fargo & Company restated an “outperform” rating and set a $54.00 price objective (up from $35.00) on shares of Juno Therapeutics in a research note on Tuesday, September 5th. Barclays started coverage on shares of Juno Therapeutics in a research note on Wednesday, September 6th. They set an “overweight” rating and a $55.00 price objective on the stock. Finally, Raymond James Financial boosted their price target on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $45.48.

In related news, General Counsel Bernard J. Cassidy sold 28,000 shares of the stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $44.92, for a total transaction of $1,257,760.00. Following the completion of the transaction, the general counsel now directly owns 55,970 shares in the company, valued at $2,514,172.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Robert Azelby sold 6,666 shares of the stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total value of $366,296.70. Following the transaction, the executive vice president now owns 79,998 shares of the company’s stock, valued at $4,395,890.10. The disclosure for this sale can be found here. Insiders sold 54,801 shares of company stock worth $2,527,741 in the last three months. Insiders own 15.08% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Juno Therapeutics, Inc. (NASDAQ:JUNO) Stake Lessened by Wasatch Advisors Inc.” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.thelincolnianonline.com/2017/12/08/wasatch-advisors-inc-reduces-position-in-juno-therapeutics-inc-juno-updated-updated.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply